Research · ACM Conference on Bioinformatics, Computational Biology, and Health Informatics 2023
SPOT
Research on clinical trial outcome prediction. SPOT predicts trial outcomes by grouping similar trials into topics, ordering them over time, and using meta-learning so the model adapts quickly to less common kinds of trial.
Who created SPOT?
SPOT was written by Keiji AI co-founders Zifeng Wang and Jimeng Sun, who is Keiji AI's CEO, with Cao Xiao. The paper lists Wang and Sun at the University of Illinois Urbana-Champaign.
What the paper found
- On trial outcome benchmark data, PR-AUC rose 21.5% on phase I, 8.9% on phase II and 5.5% on phase III trials over prior methods.
How SPOT relates to TrialMind
It is research, not a TrialMind module or a separately sold product. Published methods like this one inform how TrialMind works; TrialMind is the product Keiji AI sells.
See how TrialMind handles this work: Competitive and portfolio intelligence.
The paper
Zifeng Wang, Cao Xiao, Jimeng Sun. SPOT: Sequential Predictive Modeling of Clinical Trial Outcome with Meta-Learning. ACM Conference on Bioinformatics, Computational Biology, and Health Informatics, 2023.
Details checked against the published record on 2026-11-01.
Frequently asked questions
- Who created SPOT?
- SPOT was written by Keiji AI co-founders Zifeng Wang and Jimeng Sun, who is Keiji AI's CEO, with Cao Xiao. The paper lists Wang and Sun at the University of Illinois Urbana-Champaign.
- Is SPOT part of TrialMind?
- No. It is research, not a TrialMind module or a separately sold product. Published methods like this one inform how TrialMind works; TrialMind is the product Keiji AI sells.
- What did the SPOT paper find?
- On trial outcome benchmark data, PR-AUC rose 21.5% on phase I, 8.9% on phase II and 5.5% on phase III trials over prior methods.
All publications
Every paper sits under its primary research area.